HEPIUS Semaglutide 500mcg CAS:910463-68-2

*Semaglutide, under the HEPIUS brand, is a drug that has the same effects as glucagon-like peptide-1 (GLP-1) receptor agonists. Semaglutide is used to treat type 2 diabetes and weight management. It is characterized by enhancing insulin secretion, inhibiting glucagon secretion, delaying gastric emptying and reducing appetite by mimicking the effects of GLP-1. The following is detailed information about Semaglutide, including physical and chemical properties, dosage, half-life and usage cycle.

### **Physical and chemical properties**

1. **Molecular structure**:

- Chemical name: C187H291N45O59

- Molecular weight: 4113.58 g/mol

- Semaglutide is a modified peptide molecule that enhances the stability and duration of action of the drug by modifying the amino acid sequence of natural GLP-1.

2. **Physical properties**:

- Appearance: White to off-white powder

- Solubility: Poor solubility in water, usually used in water-soluble preparations (such as injections).

3. **Chemical stability**:

- The half-life extension is due to the introduction of specific fatty acid modifications in the peptide chain, which slows down metabolism by binding to serum albumin.

### **Dosage**

- **Diabetes treatment**:

- Initial dose: 0.25 mg, once a week, subcutaneous injection.

- Increment: can be increased to 0.5 mg once a week after 4 weeks.

- Maximum dose: 1.0 mg, once a week (can be increased to 2.0 mg in some cases, but with caution).

- **Weight loss treatment (weight management)**:

- Starting dose: 0.25 mg, once a week.

- Adjustment dose: gradually increase to 2.4 mg, once a week, and specific adjustments are made according to patient tolerance.

### **Half-life**

- Semaglutide has a half-life of approximately **7 days**, which allows it to be injected once a week, facilitating patient compliance.

- The extended half-life is mainly due to its fatty acid modification and binding to albumin, which slows down the degradation and renal clearance of the drug.

### **Pharmacokinetics**

1. **Absorption**:

- Bioavailability (subcutaneous injection): about 55%-65%.

- Onset time: a few hours to one day, depending on individual patient differences.

2. **Distribution**:

- High plasma protein binding rate (>99%), mainly bound to serum albumin.

3. **Metabolism**:

- Mainly metabolized to small peptides and amino acids through protein enzymatic hydrolysis.

4. **Excretion**:

- Metabolites are mainly excreted through urine and feces.

### **Cycle of action**

- Once-a-week dosing cycle is suitable for diabetes and weight loss treatment.

- Onset time: 1-3 days, significant effects usually appear within a few weeks.

- Steady-state concentration: Steady-state is reached after about 4-5 weeks.

### **Pharmacological action**

1. **Hypoglycemic effect**:

- Stimulates insulin secretion (glucose-dependent) through GLP-1 receptor agonism.

- Inhibits glucagon secretion and reduces liver glucose output.

2. **Weight loss effect**:

- Delays gastric emptying and increases satiety.

- Acts on the appetite regulation center of the central nervous system to reduce appetite and energy intake.

### **Precautions**

1. **Common side effects**:

- Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation.

- Fatigue, dizziness.

- Risk of pancreatitis (needs to be monitored).

2. **Contraindications**:

- Pregnant and lactating women.

- Patients with a history of allergy to Semaglutide or its components.

- Patients with medullary thyroid carcinoma or multiple endocrine neoplasia syndrome (family history).

3. **Drug interactions**:

- May affect the effects of certain drugs (such as hypoglycemic drugs, anticoagulants), and the dose should be adjusted.

### **Summary**

HEPIUS brand Semaglutide is a highly effective GLP-1 receptor agonist widely used in the treatment of type 2 diabetes and obesity. Its once-weekly dosing and good tolerability make it an important choice for patients to manage blood sugar and weight. Consult a professional medical staff before use to ensure safety and effectiveness.

*### Introduction to HEPIUS brand Semaglutide

**Semaglutide** is a drug commonly used to treat type 2 diabetes and weight management. It is developed from the GLP-1 (glucagon-like peptide-1) receptor agonist class of drugs. HEPIUS brand Semaglutide is similar to other brands in terms of function and applicability, but may have a unique dosage form or administration method, which needs to be confirmed in conjunction with brand information.

### **Applicable population**

1. **Type 2 diabetes patients**:

- Those who need to manage their condition by improving blood sugar control, especially those who cannot achieve the ideal control target through a single lifestyle intervention (diet and exercise).

- Often used in combination with other glucose-lowering drugs, such as metformin.

2. **Overweight or obese people who need to lose weight**:

- Body mass index (BMI) ≥27 (with metabolic-related diseases) or BMI ≥30.

- Particularly suitable for individuals with concomitant metabolic disorders (such as hypertension, hyperlipidemia).

3. **Patients with cardiovascular risk**:

- Semaglutide has been shown to reduce the incidence of certain high-risk cardiovascular events (such as heart attack, stroke) and is suitable for diabetic patients with relevant risks.

4. **Individuals who do not have type 2 diabetes but need to lose weight** (based on doctor's assessment):

- It can also be used for weight management under specific dose and course management.

### **How ​​it works**

Semaglutide produces a variety of metabolic improvement effects by mimicking the effects of GLP-1 (glucagon-like peptide-1):

1. **Enhanced insulin secretion**:

- When blood sugar levels rise, it stimulates pancreatic beta cells to secrete insulin and lower blood sugar levels.

2. **Inhibit glucagon secretion**:

- Reduces the secretion of glucagon by pancreatic alpha cells, thereby reducing liver glucose output.

3. **Delayed gastric emptying**:

- Slows down the speed at which gastric contents enter the small intestine, prolongs satiety, and helps control appetite and intake.

4. **Action on the central nervous system**:

- Reduce appetite and help lose weight through the appetite control center of the hypothalamus.

5. **Cardiovascular protection**:

- Reduce atherosclerosis, improve vascular function, and reduce the risk of cardiovascular disease.

### **Usage and dosage**

#### **Form of medication**:

- Injection: subcutaneous injection, common sites include abdomen, thigh or upper arm.

- Dosage and frequency of use vary according to treatment goals.

#### **Specific usage and dosage**:

1. **Type 2 diabetes treatment**:

- Starting dose: once a week, **0.25mg**.

- Gradually increase the dose: increase to **0.5mg/week** after 4 weeks; if further hypoglycemic effect is required, it can be increased to the maximum dose **1.0mg/week**.

- The injection time is fixed every week, with meals or on an empty stomach.

2. **Weight management**:

- Starting dose: **0.25mg** once a week to reduce gastrointestinal adverse reactions.

- Gradually increase the dose: gradually increase to **2.4mg/week** (target dose) after 4 weeks.

- Low-calorie diet and regular exercise are required.

#### **Precautions**:

- Do not stop taking the drug suddenly, and the dose needs to be adjusted under the guidance of a doctor.

- Nausea, vomiting, diarrhea and other discomforts may occur in the early stage, which generally subside over time.

- Avoid use in patients with type 1 diabetes or diabetic ketoacidosis.

- Patients with impaired liver and kidney function, pregnant women and breastfeeding women should use it with caution and follow the doctor's advice.

### **Summary**

HEPIUS brand Semaglutide is a highly effective and safe GLP-1 receptor agonist suitable for type 2 diabetes and weight management, but the medication must be strictly followed according to the doctor's instructions. Combined with a healthy lifestyle, it plays an important role in the comprehensive management of metabolic diseases and helps improve blood sugar, weight and cardiovascular health.

Semaglutide is a GLP-1 receptor agonist used to treat type 2 diabetes and obesity. HEPIUS brand Semaglutide is attracting more and more attention from patients and medical institutions due to its unique advantages and quality. The following are the detailed advantages of HEPIUS brand Semaglutide:

### **1. Drug quality and production standards**

HEPIUS brand Semaglutide is produced in strict accordance with international advanced pharmaceutical processes and quality standards:

- **High-purity raw materials**: Use high-quality active pharmaceutical ingredients (API) to ensure significant efficacy and low side effects.

- **Advanced production technology**: Using the latest biotechnology platform to ensure molecular stability and longer-lasting drug activity.

- **Strict quality control process**: From research and development to production, we comply with GMP (Good Manufacturing Practice) throughout the process to ensure the safety and consistency of drugs.

### **2. Treatment Advantages**

HEPIUS-branded Semaglutide is particularly effective in the treatment of diabetes and obesity:

- **Significant blood sugar control effect**: By mimicking the effects of GLP-1 (glucagon-like peptide-1), it increases insulin secretion, inhibits glucagon secretion, and helps patients better control blood sugar.

- **Promotes Weight Management**: Significantly suppresses appetite and delays gastric emptying to aid in long-term weight loss. Studies have shown that Semaglutide can help obese patients lose an average of more than 10% of their weight.

- **Cardiovascular protection**: Reduce the risk of cardiovascular disease, including reducing the probability of myocardial infarction, stroke and other events.

- **Long-term effect**: With a once-weekly injection regimen, the drug has a long half-life and patients have higher compliance.

### **3. Ease of use**

HEPIUS branded semaglutide is available in a variety of dosage forms and strengths to meet the needs of different patients:

- **Prefilled injection pen**: simple design, precise dosage, convenient for patients to use by themselves, reducing the psychological burden during the injection process.

- **Once-weekly injection**: Semaglutide greatly improves the convenience of patients compared to daily oral medication or frequent injections.

### **4. Personalized medical support**

HEPIUS brand focuses on providing patients with comprehensive medical support:

- **Detailed patient education**: including guidance on medication use and health management plans to help patients better understand and manage their diseases.

- **Health data monitoring**: Use smart apps or remote monitoring services to track key health indicators such as blood sugar and weight in real time.

- **Nutrition and exercise advice**: Combined with medication, we tailor a personalized diet and exercise plan for patients to help achieve the best treatment results.

### **5. Fewer side effects**

HEPIUS brand semaglutide has been optimized to minimize the incidence of common side effects:

- **Improved gastrointestinal tolerance**: Some patients may experience mild nausea or vomiting, but the symptoms are usually transient and alleviated with prolonged use.

- **Low Risk of Hypoglycemia**: Semaglutide has a lower risk of hypoglycemia when used alone compared to certain other glucose-lowering medicines.

### **6. Global Recognition and Clinical Data Support**

HEPIUS-branded Semaglutide has been certified by international authorities, and clinical research results have further verified its safety and effectiveness:

- **Large clinical trials**: Studies such as STEP and SUSTAIN have shown that Semaglutide is effective in treating diabetes and obesity.

- **Widely applicable population**: including patients with type 2 diabetes, obese or overweight people, and patients who need to control cardiovascular risks.

### **7. Cost-effectiveness**

HEPIUS-branded Semaglutide provides cost-effective treatment options by optimizing production processes and supply chain management, making high-quality treatments affordable to more patients.

### **8. Environmental and Social Responsibility**

HEPIUS brand attaches great importance to sustainable development:

- **Environmentally friendly production**: Use green pharmaceutical technology to reduce the impact on the environment.

- **Social Support Program**: Through patient assistance programs, we provide drug support to patients with financial difficulties and improve medical equity.

HEPIUS-branded Semaglutide has become a leader in the treatment of diabetes and obesity with its excellent efficacy, high-quality production standards and comprehensive patient support system. Whether it is the pursuit of therapeutic effects for patients or the contribution to the overall medical ecology, the HEPIUS brand has demonstrated outstanding competitiveness and social responsibility.

WhatsApp/Telegram:+852 6749 2648

Gmail:lucasraws207@gmail.com

Skype：live:.cid.8f21dc7fc6621ba7

Hot Tags: hepius semaglutide 500mcg cas:910463-68-2, China hepius semaglutide 500mcg cas:910463-68-2 manufacturers, suppliers, factory, Viagra CAS 139755 83 2, Methyltrienolone Highly effective fat reduction, steroid finished tablets, Methyltrienolone CAS 965 93 5, T3 CAS 6893 02 3, Viagra Improves the pump and muscle definition during training